India markets open in 8 hours 59 minutes

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8550+0.1250 (+4.58%)
As of 2:44PM EDT. Market open.
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    BELLUS Health is up 6.59% to 2.91
  • M
    Mr. Gillis
    I dont understand why this goes down??? Does somebody know when the trail 2b results will come?
  • M
    Mr. Gillis
    What s the opinion on the phase 2b here? Will this stock go back to 10?
  • Y
    Yahoo Finance Insights
    BLU.TO is up 6.19% to 3.60
  • s
    stephen
    shorts are covering and more institutions are buying but stock price still down what's upπŸ€”
  • I
    Investrman
    so folks, what is going on here with this company??? This stock was $12.00 not very long ago...??
  • T
    Tony
    minus 2 BLU a champion amongst champions. Hello bag holders! I see nothing much has changed since I last posted here. Well there was that pump and dump but the dumping continues
  • k
    kevin
    This is on Zack’s sell list. I think it’s just down because of uncertainty on clinical phase 3 info. Any opinions, guys?
  • Y
    Yahoo Finance Insights
    BLU.TO is up 6.07% to 3.67
  • Y
    Yahoo Finance Insights
    BLU.TO is up 6.65% to 3.69
  • O
    OSAMA
    Mark my words, by July 7
  • Y
    Yahoo Finance Insights
    BELLUS Health is up 6.18% to 2.92
  • Y
    Yahoo Finance Insights
    BLU.TO is down 7.18% to 3.36
  • Y
    Yahoo Finance Insights
    BELLUS Health is down 7.24% to 2.69
  • D
    DipBuy$$$
    It’s going up again πŸš€
  • A
    Albert
    Nobody trade?
  • R
    Ram
    Huge bull call.. upgrade with target to $12... 400% upside that is the reason stock is moving up,,,

    https://seekingalpha.com/news/3637474-huge-bull-call-on-bellus-health-from-evercore-impliesplus-400-upside
    Stock Picks, Stock Market Investing
    seekingalpha.com
  • B
    Bildo
    From the Bellus web site: "second half of 2020"

    BELLUS Health believes BLU-5937 may be a viable treatment option for patients with chronic pruritus associated with atopic dermatitis. The Company has conducted preclinical studies of BLU-5937 in pruritus, and expects to initiate a Phase 2 trial to assess the efficacy, safety, and tolerability of BLU-5937 versus placebo in approximately 100 patients suffering from chronic pruritus associated with mild to moderate atopic dermatitis in the second half of 2020.
  • J
    J
    People always take profit when there is an announcement of Phase trials where the instant gratification is not there... BLU will continue to steadily climb. Those cashing in will regret it.
  • V
    Victor
    Spoke with Danny Matthews yesterday about upcoming events etc. Bio conference in 5 weeks, earnings August 13th (of course as a clinical stage biotech, I expect minimal revenue but more interested in updates and announcements). Stock is trading at only 2 times cash and extremely undervalued. Executives loading up is a major vote of confidence as well as some tunes that have been increasing their positions.